Status:
UNKNOWN
Effect of Terlipressinum on the Portal Vein Pressure of Patients With Liver Tumor After Liver Resection
Lead Sponsor:
Shanghai Zhongshan Hospital
Conditions:
Portal Vein Pressure
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
In this study, investigators aim to screen out the patients with portal hypertension by monitoring intraoperative PVP, and to decide the effect of Terlipressinum on the portal pressure after liver res...
Detailed Description
Liver resection is a common treatment for liver tumors. But the incidence of postoperative liver failure after hepatectomy is as high as 9-18.6%, which results in relatively high mortality rate . Port...
Eligibility Criteria
Inclusion
- Patients who receives liver resection.
- PVP is more than 12mmHg in 5 minutes after liver resection.
Exclusion
- Age: \<18, \>75;
- Portal vein tumor thrombus is confirmed by preoperative assays;
- Obstruction of biliary tract;
- Active hepatitis;
- Previous history of myocardial infarction;
- Previous history of chronic kidney disease;
- Severe arrhythmia;
- Any other contraindications of the Terlipressinum.
Key Trial Info
Start Date :
December 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2018
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03352349
Start Date
December 1 2017
End Date
December 30 2018
Last Update
November 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital
Shanghai, Shanghai Municipality, China, 200032